...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Data Expected September 2019 for BETonMACE Phase 3 Cardiovascular Outcomes Trial for Apabetalone


BREAKING: Spyder Cannabis Receives Approval on Development Permit for its Flagship Cannabis Store in Calgary, Alberta

  • Received approval on their development permit for a flagship retail location in the heart of Calgary
  • Spyder has now been accepted by Alberta Health Services and will begin construction in the coming weeks.
  • This brings Spyder’s total retail to 6 locations across Ontario and Alberta, this number is expected to grow over the coming months.

Spdr logo large

Hub On AGORACOM / Read Release

Message: What if

No problem RVXoldtimer. Like most on this board, I'm not too worried about the aminotransferase issue. However, I do feel it is important for all here to be armed with enough detailed info on this subject to be ready to come to the defense when the bashers come. Between the time period of end of dosing and top-line, and especially between top-line and full data, I expect more attention. Once more attention is on Resverlogix and BETonMACE, it won't all be good attention. There will be some folks out there taking swings at Resverlogix/BETonMACE/apabetalone. Once full data is presented, all the cards should be on the table in terms of safety. But until that time, don't be surprised if the haters start hating on this. It's just par for the course. All just my opinion.


New Message
Please login to post a reply